NEUCHATEL, SWITZERLAND--(Marketwired - Oct 10, 2014) - Masimo (NASDAQ: MASI), maker of breakthrough Masimo SET ® Measure-through Motion and Low Perfusion™ Pulse Oximetry, today announced the CE Mark ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...

Masimo Corporation (NASDAQ:MASI) received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering ...

ZURICH, SWITZERLAND and IRVINE, CA--(Marketwired - Nov 22, 2013) - Masimo (NASDAQ: MASI) announced today that ACUTRONIC Medical Systems AG has integrated Masimo SET ® Measure-through Motion and Low ...

Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...

Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...

Smaller, Flexible Sensors Are More Comfortable for Patients, Easier to Apply for Clinicians "Masimo's new low-profile sensors are not only flatter and easier to apply, but the added pliability allows ...

Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among ...

Using less than 45 milliwatts of power, Masimo MS-2040 boards are available in both a double-stack version (pictured) with dimensions of 1.8″ x 1.15″ x 0.46″ and single-stack version with dimensions ...